Krummenacher Isabelle, Cavassini Matthias, Bugnon Olivier, Schneider Marie P
Community Pharmacy Research Unit, Pharmaceutical Sciences Section, Universities of Geneva & Lausanne, Lausanne, Switzerland.
AIDS Care. 2011 May;23(5):550-61. doi: 10.1080/09540121.2010.525613.
To ensure successful treatment, HIV patients must maintain a high degree of medication adherence over time. Since August 2004, patients who are (or are at risk of) experiencing problems with their HIV antiretroviral therapy (ART) have been referred by their physicians to an interdisciplinary HIV-adherence program. The program consists of a multifactorial intervention along with electronic drug monitoring (MEMS(TM)). The pharmacists organize individualized semi-structured motivational interviews based on cognitive, emotional, behavioral, and social issues. At the end of each session, the patient brings an adherence report to the physician. This enables the physician to use the adherence results to evaluate the treatment plan. The aim of this study was to retrospectively analyze this on-going interdisciplinary HIV-adherence program. All patients who were included between August 2004 and the end of April 2008 were analyzed. One hundred and four patients were included (59% women, median age 39 (31.0, 46.0) years, 42% black ethnicity). Eighty (77%) patients were ART-experienced patients and 59% had a protease inhibitor-based treatment. The retention rate was high (92%) in the program. Patient inclusion in this HIV-adherence program was determined by patient issues for naive patients and by nonadherence or suboptimal clinical outcomes for ART-experienced patients. The median time spent by a subject at the pharmacy was 35 (25.0, 48.0) minutes, half for the medication handling and half for the interview. The adherence results showed a persistence of 87% and an execution of 88%. Proportion of undetectable subjects increased during study. In conclusion, retention and persistence rates were high in this highly selected problematic population.
为确保治疗成功,艾滋病病毒(HIV)患者必须长期高度坚持服药。自2004年8月以来,正在接受(或有风险接受)HIV抗逆转录病毒治疗(ART)且出现问题的患者已被其医生转介至一个跨学科的HIV服药依从性项目。该项目包括多因素干预以及电子药物监测(MEMS™)。药剂师根据认知、情感、行为和社会问题组织个性化的半结构化动机访谈。在每次访谈结束时,患者会将服药依从性报告带给医生。这使医生能够利用依从性结果来评估治疗方案。本研究的目的是对这个正在进行的跨学科HIV服药依从性项目进行回顾性分析。对2004年8月至2008年4月底纳入的所有患者进行了分析。共纳入104例患者(59%为女性,年龄中位数为39(31.0,46.0)岁,42%为黑人)。80例(77%)患者有ART治疗经验,59%接受基于蛋白酶抑制剂的治疗。该项目的留存率很高(92%)。对于初治患者,是否纳入该HIV服药依从性项目由患者自身问题决定;对于有ART治疗经验的患者,则由不依从或次优临床结果决定。患者在药房花费的时间中位数为35(25.0,48.0)分钟,一半用于药物处理,一半用于访谈。依从性结果显示持续率为87%,执行率为88%。在研究期间,病毒载量不可检测的患者比例有所增加。总之,在这个经过高度筛选的问题人群中,留存率和持续率都很高。